Stockscreener 앱 받기
26.11
12.20%
2.84
시간 외 거래:
25.00
-1.11
-4.25%
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% HigherWhat's Next? - MarketBeat
ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Nigeria
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - Bluefield Daily Telegraph
Zenas BioPharma Announces Late-Breaking Platform - GlobeNewswire
Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm
Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq
Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
A Big Boss Bet on Zenas BioPharma’s Future - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys 57,000 Shares - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 8.9%Here's Why - MarketBeat
Chipmakers Recap: What is the target price for Zenas BioPharma Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - GlobeNewswire Inc.
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Published on: 2026-02-01 19:33:40 - baoquankhu1.vn
Investment Report: What are analysts price targets for ArrowMark Financial CorpWeekly Investment Summary & Daily Stock Momentum Reports - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Is Zenas BioPharma Inc.’s growth already priced in2025 Top Gainers & Safe Entry Trade Reports - mfd.ru
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - Chartmill
Zenas BioPharma Slams Investor's Revamped Fraud Claim - Law360
Can Zenas BioPharma Inc be the next market leaderOptions Play & Short-Term High Return Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma (ZBIO) Stock Analysis: Promising 99.75% Upside Potential For Investors - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPhar - The National Law Review
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 6.6%Here's Why - MarketBeat
Zenas Bio rises as Wedbush launches with Outperform on lead asset - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contac - The National Law Review
Zenas BioPharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Zenas crashes as late-stage trial data for lead asset disappoint - MSN
Portfolio Update: Will Zenas BioPharma Inc outperform during market ralliesWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Moving Averages: Can Northann Corp navigate macro headwindsPortfolio Return Summary & Comprehensive Market Scan Reports - baoquankhu1.vn
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1%Time to Sell? - MarketBeat
Zenas BioPharma Stock Pre-Market (-4.4%): Shareholder Lawsuit Investigation Announced - Trefis
Assessing Zenas BioPharma (ZBIO) Valuation After Phase 3 INDIGO Success And CEO Share Purchase - Sahm
1.24%
0.19%
자본화:
|
볼륨(24시간):